Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Aug;108(3):437-46.
doi: 10.1172/JCI11559.

Prevention of fat-induced insulin resistance by salicylate

J K Kim  1 , Y J Kim, J J Fillmore, Y Chen, I Moore, J Lee, M Yuan, Z W Li, M Karin, P Perret, S E Shoelson, G I Shulman
Affiliations

Prevention of fat-induced insulin resistance by salicylate

J K Kim et al. J Clin Invest. 2001 Aug.

Abstract

Insulin resistance is a major factor in the pathogenesis of type 2 diabetes and may involve fat-induced activation of a serine kinase cascade involving IKK-beta. To test this hypothesis, we first examined insulin action and signaling in awake rats during hyperinsulinemic-euglycemic clamps after a lipid infusion with or without pretreatment with salicylate, a known inhibitor of IKK-beta. Whole-body glucose uptake and metabolism were estimated using [3-(3)H]glucose infusion, and glucose uptake in individual tissues was estimated using [1-(14)C]2-deoxyglucose injection during the clamp. Here we show that lipid infusion decreased insulin-stimulated glucose uptake and activation of IRS-1-associated PI 3-kinase in skeletal muscle but that salicylate pretreatment prevented these lipid-induced effects. To examine the mechanism of salicylate action, we studied the effects of lipid infusion on insulin action and signaling during the clamp in awake mice lacking IKK-beta. Unlike the response in wild-type mice, IKK-beta knockout mice did not exhibit altered skeletal muscle insulin signaling and action following lipid infusion. In summary, high-dose salicylate and inactivation of IKK-beta prevent fat-induced insulin resistance in skeletal muscle by blocking fat-induced defects in insulin signaling and action and represent a potentially novel class of therapeutic agents for type 2 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Metabolic parameters and insulin-stimulated whole-body and skeletal muscle (soleus) glucose uptake in awake control (black bars), salicylate (light gray bars), lipid (open bars), and lipid-salicylate (dark gray bars) rats. (a) Plasma salicylate concentrations during basal and hyperinsulinemic-euglycemic clamp. (b) Plasma FFA concentrations during basal and hyperinsulinemic-euglycemic clamp. (c) Insulin-stimulated whole-body glucose uptake in vivo. (d) Insulin-stimulated skeletal muscle glucose uptake in vivo. Values are means ± SE for six to seven experiments. *P < 0.05 versus control group.
Figure 2
Figure 2
Insulin-stimulated whole-body and skeletal muscle (soleus) glucose metabolic flux in awake control (black bars), salicylate (light gray bars), lipid (open bars), and lipid-salicylate (dark gray bars) rats. (a) Insulin-stimulated whole-body glycolysis in vivo. (b) Insulin-stimulated whole-body glycogen/lipid synthesis in vivo. (c) Insulin-stimulated skeletal muscle glycolysis in vivo. (d) Insulin-stimulated skeletal muscle glycogen synthesis in vivo. Values are means ± SE for six to seven experiments. *P < 0.05 versus control group.
Figure 3
Figure 3
Insulin signaling in skeletal muscle (gastrocnemius) of the control (black bars), salicylate (light gray bars), lipid (open bars), and lipid-salicylate (dark gray bars) rats. (a) Insulin-stimulated tyrosine phosphorylation of insulin receptor. (b) Insulin-stimulated tyrosine phosphorylation of IRS-1. (c) Insulin-stimulated IRS-1–associated PI 3-kinase activity. Values are means ± SE for six to seven experiments. *P < 0.05 versus control group.
Figure 4
Figure 4
Insulin action in liver and epididymal white adipose tissue in the control (black bars), salicylate (light gray bars), lipid (open bars), and lipid-salicylate rats (dark gray bars). (a) Basal rates of endogenous glucose production. (b) Percent suppression of basal endogenous glucose production during insulin-stimulated state. (c) Insulin-stimulated glucose uptake in epididymal white adipose tissue. Values are means ± SE for six to seven experiments.
Figure 5
Figure 5
Metabolic parameters and insulin-stimulated whole-body and skeletal muscle (gastrocnemius) glucose uptake in awake control (black bars), IKK-β KO (light gray bars), control-lipid (open bars), and IKK-β KO-lipid (dark gray bars) mice. (a) Plasma FFA concentrations during basal and hyperinsulinemic-euglycemic clamp. (b) Insulin-stimulated percent suppression of basal EGP. (c) Insulin-stimulated whole-body glucose uptake in vivo. (d) Insulin-stimulated skeletal muscle glucose uptake in vivo. Values are means ± SE for three to five experiments. *P < 0.05 versus control group; †P < 0.05 versus IKK-β KO-lipid group.
Figure 6
Figure 6
Insulin-stimulated whole-body and skeletal muscle (gastrocnemius) glucose metabolic flux in awake control (black bars), IKK-β KO (light gray bars), control-lipid (open bars), and IKK-β KO-lipid (dark gray bars) mice. (a) Insulin-stimulated whole-body glycolysis in vivo. (b) Insulin-stimulated whole-body glycogen/lipid synthesis in vivo. (c) Insulin-stimulated skeletal muscle glycolysis in vivo. (d) Insulin-stimulated skeletal muscle glycogen synthesis in vivo. Values are means ± SE for three to five experiments. *P < 0.05 versus control group; †P < 0.05 versus IKK-β KO-lipid group.
Figure 7
Figure 7
Insulin signaling in skeletal muscle (gastrocnemius) and insulin action in fat of the control (black bars), IKK-β KO (light gray bars), control-lipid (open bars), and IKK-β KO-lipid (dark gray bars) mice. (a) Insulin-stimulated tyrosine phosphorylation of IRS-1 in skeletal muscle. (b) Insulin-stimulated IRS-1–associated PI 3-kinase activity in skeletal muscle. (c) Insulin-stimulated glucose uptake in intrascapular brown adipose tissue. (d) Insulin-stimulated glucose uptake in epididymal white adipose tissue. Values are means ± SE for three to five experiments. *P < 0.05 versus control group; †P < 0.05 versus IKK-β KO-lipid group.
See this image and copyright information in PMC

Comment in

  • Turning down insulin signaling.
    Birnbaum MJ. Birnbaum MJ. J Clin Invest. 2001 Sep;108(5):655-9. doi: 10.1172/JCI13714. J Clin Invest. 2001. PMID: 11544268 Free PMC article. No abstract available.
  • The effect of salicylates on insulin sensitivity.
    Netea MG, Tack CJ, Netten PM, Lutterman JA, Van der Meer JW. Netea MG, et al. J Clin Invest. 2001 Dec;108(11):1723-4. doi: 10.1172/JCI14455. J Clin Invest. 2001. PMID: 11733568 Free PMC article. No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. DeFronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667–687. - PubMed
    1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607. - PubMed
    1. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3–10. - PubMed
    1. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–789. - PubMed
    1. Kelley DE, Mokan M, Simoneau J-A, Mandarino LJ. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest. 1993;92:91–98. - PMC - PubMed

Publication types

MeSH terms